LXRX - Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting | Benzinga
Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1
INPEFA recently approved by FDA for treatment of heart failure
Abstracts published in the Journal of Managed Care & Specialty Pharmacy (JMCP)
THE WOODLANDS, Texas, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that findings from two studies on the cost-effectiveness and budget impact of INPEFA® (sotagliflozin) will be presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting on October 16-19, 2023, in Orlando, Florida.
Both posters will be on display Tuesday, October 17, 2023, from 4:00 – 7:00 p.m. ET during the Opening Night Reception at the Orlando World Center Marriott, Expo Hall, Cypress 1 and 2, and will be included in the meeting's first session of poster presentations on Wednesday, October 18, 2023, from 11:00 a.m. – 12:30 p.m. ET in the same location.
Details of the presentations are as follows:
- Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure – poster # I5, presented by Jaehong Kim, PhD, FTI Consulting Center for Healthcare Economics and Policy, Los Angeles, California
- Economic impact of sotagliflozin among patients with heart failure: budget impact analysis from US payer perspective– poster # I7, presented by Shanshan Wang, MPH, FTI Consulting Center for Healthcare Economics and Policy, Los Angeles, California
Abstracts for each study are available in the Poster Abstracts Supplement to the Journal of Managed Care & Specialty Pharmacy (JMCP), which can be found here.
"We believe that the cost-effectiveness analysis and budget impact model for INPEFA will be crucial in driving decisions for formulary inclusion of this important innovation," said Craig Granowitz, M.D., Ph.D., Lexicon's senior vice president and chief medical officer. "The data presented at this meeting and beyond continues to support and differentiate the value of INPEFA for patients with heart failure."
On May 26, 2023, the U.S. Food and Drug Administration approved INPEFA, a once-daily oral tablet, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with:
- heart failure or
- type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat diseases safely and effectively. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in heart failure, neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
About INPEFA® (sotagliflozin)
Discovered using Lexicon's unique approach to gene science, INPEFA® (sotagliflozin) is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and ...